{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T15:00:10Z","timestamp":1763564410741,"version":"3.45.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005765","name":"Universidade de Lisboa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005765","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Monitoring safety throughout a medicine\u2019s lifecycle is essential. Pharmacovigilance systems are rich sources contributing to this aim in a real world context.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To identify and estimate disproportionality rates associated with the drugs that are most frequently reported to induce acute kidney injury (AKI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A case\/non-case study was conducted, using data extracted in 2022 from the Portuguese National Pharmacovigilance Database for the period between 01\/01\/2009 and 12\/31\/2020. Cases were identified using the \u2018Acute Renal Failure\u2019 standardized MedDRA query, all remaining reports were considered non-cases, and a random sample without replacement of 4 non-cases per case was extracted. Data were expressed as the reporting odds ratio (ROR) and the 95% confidence interval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During this 11-year period, 352 AKI cases were identified, representing 0.7% of the 53,505 reports received. A total of 559 different drugs were considered 'suspect' in these AKI cases. Three therapeutic subgroups (ATC2) showed a significant ROR: antithrombotic agents (ROR 6.72; 95% CI 2.23\u201320.22), antivirals for systemic use (ROR 4.02; 95% CI 2.76\u20135.87), and antineoplastic drugs (ROR 2.14; 95% CI 1.48\u20133.11). Additionally, we identified individual drugs with significant RORs where no class effect was observed, namely mycophenolic acid, ciclosporin, tacrolimus, simvastatin, prednisolone, vancomycin, and deferasirox. In total, eleven drugs were identified as potentially associated with the occurrence of AKI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study highlights the importance of clinical pharmacy activities in closely monitoring renal function of people with known risk factors or those prescribed medications known to increase the risk of AKI. Some of the medications identified require further investigation to validate their association with AKI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11096-025-01940-0","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T07:27:33Z","timestamp":1748244453000},"page":"1730-1738","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A case\/non-case study of a national pharmacovigilance database to explore drug-induced acute kidney injury"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-2717","authenticated-orcid":false,"given":"Catarina Luz","family":"Oliveira","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8529-9595","authenticated-orcid":false,"given":"Fernando","family":"Fernandez-Llimos","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0562-2514","authenticated-orcid":false,"given":"Filipa","family":"Alves da Costa","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5799-3088","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Aguiar","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6632-2553","authenticated-orcid":false,"given":"Filipa","family":"Duarte-Ramos","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"issue":"1","key":"1940_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1056\/NEJMra1214243","volume":"371","author":"LS Chawla","year":"2014","unstructured":"Chawla LS, Eggers PW, Star RA, et al. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014;371(1):58\u201366.","journal-title":"N Engl J Med"},{"issue":"9","key":"1940_CR2","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1007\/s40620-022-01381-2","volume":"35","author":"K Stille","year":"2022","unstructured":"Stille K, Kribben A, Herget-Rosenthal S. Incidence, severity, risk factors and outcomes of acute kidney injury in older adults: systematic review and meta-analysis. J Nephrol. 2022;35(9):2237\u201350.","journal-title":"J Nephrol"},{"issue":"10474","key":"1940_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0140-6736(24)02385-7","volume":"405","author":"M Ostermann","year":"2025","unstructured":"Ostermann M, Lumlertgul N, Jeong R, et al. Acute kidney injury. Lancet. 2025;405(10474):241\u201356.","journal-title":"Lancet"},{"key":"1940_CR4","unstructured":"Acute kidney injury: prevention, detection and management. National Institute for Health and Care Excellence: Clinical Guidelines (NG148). London. 2024. Available at https:\/\/www.nice.org.uk\/guidance\/ng148. Accessed 5 May 2025."},{"key":"1940_CR5","unstructured":"Kidney Disease: Improving Global Outcome (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guidelines for acute kidney injury. Kidney Int Suppl. 2012;2:138. Available at https:\/\/kdigo.org\/guidelines\/acute-kidney-injury\/. Accessed 15 September 2023."},{"issue":"4","key":"1940_CR6","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.ccc.2015.06.005","volume":"31","author":"SL Kane-Gill","year":"2015","unstructured":"Kane-Gill SL, Goldstein SL. Drug-induced acute kidney injury: a focus on risk assessment for prevention. Crit Care Clin. 2015;31(4):675\u201384.","journal-title":"Crit Care Clin"},{"issue":"6","key":"1940_CR7","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/bcp.13216","volume":"83","author":"M Pierson-Marchandise","year":"2017","unstructured":"Pierson-Marchandise M, Gras V, Moragny J, et al. The drugs that mostly frequently induce acute kidney injury: a case\u2013noncase study of a pharmacovigilance database. Br J Clin Pharmacol. 2017;83(6):1341\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1940_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/jcpt.12748","volume":"44","author":"K Hosohata","year":"2019","unstructured":"Hosohata K, Inada A, Oyama S, et al. Surveillance of drugs that most frequently induce acute kidney injury: a pharmacovigilance approach. J Clin Pharm Ther. 2019;44(1):49\u201353.","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"1940_CR9","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/pds.5108","volume":"29","author":"S Hasegawa","year":"2020","unstructured":"Hasegawa S, Ikesue H, Nakao S, et al. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. Pharmacoepidemiol Drug Saf. 2020;29(10):1279\u201394.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"1940_CR10","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/cpt.2145","volume":"109","author":"AO G\u00e9rard","year":"2021","unstructured":"G\u00e9rard AO, Laurain A, Fresse A, et al. Remdesivir and acute renal failure: a potential safety signal from disproportionality analysis of the WHO safety database [published correction appears in Clin Pharmacol Ther. 2022;111(6):1343.]. Clin Pharmacol Ther. 2021;109(4):1021\u20134.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1940_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/JCP.0000000000000094","volume":"34","author":"F Montastruc","year":"2014","unstructured":"Montastruc F, Scotto S, Vaz IR, et al. Hepatotoxicity related to agomelatine and other new antidepressants: a case\/noncase approach with information from the Portuguese, French, Spanish, and Italian pharmacovigilance systems. J Clin Psychopharmacol. 2014;34(3):327\u201330.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"1940_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/14740338.2018.1439474","volume":"17","author":"D Caldeira","year":"2018","unstructured":"Caldeira D, Rodrigues R, Abreu D, et al. Suspected adverse drug reaction reports with oral anticoagulants in Portugal: a pharmacovigilance study. Expert Opin Drug Saf. 2018;17(4):339\u201345.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"1940_CR13","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/jcpt.12148","volume":"39","author":"D Mendes","year":"2014","unstructured":"Mendes D, Alves C, Batel-Marques F. Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events. J Clin Pharm Ther. 2014;39(3):307\u201313.","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"1940_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"JL Faillie","year":"2019","unstructured":"Faillie JL. Case-non-case studies: Principle, methods, bias and interpretation. Therapie. 2019;74(2):225\u201332.","journal-title":"Therapie"},{"key":"1940_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.euroneuro.2020.03.022","volume":"35","author":"JP Aguiar","year":"2020","unstructured":"Aguiar JP, Alves da Costa F, Egberts T, et al. The association between receptor binding affinity and metabolic side effect profile of antipsychotics and major cardio- and cerebrovascular events: A case\/non-case study using VigiBase. Eur Neuropsychopharmacol. 2020;35:30\u20138.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"1940_CR16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1365-2125.2009.03596.x","volume":"69","author":"G Montastruc","year":"2010","unstructured":"Montastruc G, Favreliere S, Sommet A, et al. Drugs and dilated cardiomyopathies: a case\/noncase study in the French PharmacoVigilance Database. Br J Clin Pharmacol. 2010;69(3):287\u201394.","journal-title":"Br J Clin Pharmacol"},{"key":"1940_CR17","unstructured":"Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008. ISBN-13. 978-1451190052."},{"key":"1940_CR18","unstructured":"Farmacovigil\u00e2ncia - INFARMED, I.P. https:\/\/app10.infarmed.pt\/e_book_farmacovigilancia25\/index.html Accessed 15 September 2023."},{"issue":"2","key":"1940_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109\u201317.","journal-title":"Drug Saf"},{"key":"1940_CR20","unstructured":"Beers MH. The Merck Manual. 17th ed. Rahway: Merck Publishing; 1999. ISBN-13. 978-0911910100."},{"key":"1940_CR21","unstructured":"Smith LH, Wyngaarden JB. Cecil Textbook of Medicine. 19th ed. Philadelphia: W B Saunders Co Publishing; 1991. ISBN 13: 9780721629315."},{"key":"1940_CR22","unstructured":"Isselbacher E, Braunwald KJ, Wilson JD, et al. Harrison\u2019s Principles of Internal Medicine. 13th ed. New York: McGraw-Hill Publishing; 1994. ISBN-13, 978-0070709102."},{"key":"1940_CR23","unstructured":"STATA SE. Statistical software for data science. version 15.1."},{"key":"1940_CR24","unstructured":"Anatomical Therapeutic Chemical (ATC) Classification. https:\/\/atcddd.fhi.no\/atc_ddd_index\/. Accessed 15 September 2023."},{"issue":"4","key":"1940_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1469-1809.1955.tb01348.x","volume":"19","author":"B Woolf","year":"1955","unstructured":"Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet. 1955;19(4):251\u20133.","journal-title":"Ann Hum Genet"},{"issue":"2","key":"1940_CR26","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11096-023-01554-4","volume":"45","author":"X Li","year":"2023","unstructured":"Li X, Zhou L, Gaggl M, et al. Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the U.S. Food and Drug Administration Adverse Event Reporting System. Int J Clin Pharm. 2023;45(2):509\u201314.","journal-title":"Int J Clin Pharm"},{"issue":"Suppl 1","key":"1940_CR27","doi-asserted-by":"publisher","first-page":"s82","DOI":"10.1590\/1806-9282.66.s1.82","volume":"66Suppl 1","author":"GTM Sales","year":"2020","unstructured":"Sales GTM, Foresto RD. Drug-induced nephrotoxicity. Rev Assoc Med Bras (1992). 2020;66Suppl 1(Suppl 1):s82\u201390.","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"1940_CR28","first-page":"457","volume":"7","author":"GS Pazhayattil","year":"2014","unstructured":"Pazhayattil GS, Shirali AC. Drug-induced impairment of renal function. Int J Nephrol Renovasc Dis. 2014;7:457\u201368.","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"12","key":"1940_CR29","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/ki.2010.475","volume":"81","author":"MA Perazella","year":"2012","unstructured":"Perazella MA. Drug use and nephrotoxicity in the intensive care unit. Kidney Int. 2012;81(12):1172\u20138.","journal-title":"Kidney Int"},{"issue":"1","key":"1940_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1053\/j.ackd.2019.08.001","volume":"27","author":"MC Morales-Alvarez","year":"2020","unstructured":"Morales-Alvarez MC. Nephrotoxicity of antimicrobials and antibiotics. Adv Chronic Kidney Dis. 2020;27(1):31\u20137.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"12","key":"1940_CR31","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.2215\/CJN.00150118","volume":"13","author":"MA Perazella","year":"2018","unstructured":"Perazella MA. Pharmacology behind Common Drug Nephrotoxicities. Clin J Am Soc Nephrol. 2018;13(12):1897\u2013908.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"1940_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0168-8278(95)80428-5","volume":"22","author":"MI Lucena","year":"1995","unstructured":"Lucena MI, Andrade RJ, Cabello MR, et al. Aminoglycoside-associated nephrotoxicity in extrahepatic obstructive jaundice. J Hepatol. 1995;22(2):189\u201396.","journal-title":"J Hepatol"},{"issue":"6","key":"1940_CR33","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1046\/j.1365-2796.2003.01146.x","volume":"253","author":"G Gambaro","year":"2003","unstructured":"Gambaro G, Perazella MA. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med. 2003;253(6):643\u201352.","journal-title":"J Intern Med"},{"issue":"6","key":"1940_CR34","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.semnephrol.2010.09.005","volume":"30","author":"MA Perazella","year":"2010","unstructured":"Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention\/therapy. Semin Nephrol. 2010;30(6):570\u201381.","journal-title":"Semin Nephrol"},{"issue":"5","key":"1940_CR35","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/ki.2015.30","volume":"87","author":"MA Perazella","year":"2015","unstructured":"Perazella MA, Izzedine H. New drug toxicities in the onco-nephrology world. Kidney Int. 2015;87(5):909\u201317.","journal-title":"Kidney Int"},{"issue":"4","key":"1940_CR36","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.amjmed.2008.11.025","volume":"122","author":"F Gurevich","year":"2009","unstructured":"Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med. 2009;122(4):322\u20138.","journal-title":"Am J Med"},{"issue":"12","key":"1940_CR37","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1161\/10.1161\/01.ATV.0000194548.11901.a4","volume":"25","author":"MJ Chapman","year":"2005","unstructured":"Chapman MJ, Carrie A. Mechanisms of statin-induced myopathy: a role for the ubiquitin-proteasome pathway? Arterioscler Thromb Vasc Biol. 2005;25(12):2441\u20134.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"1940_CR38","doi-asserted-by":"publisher","first-page":"930","DOI":"10.2215\/CJN.10051012","volume":"8","author":"M Zaidan","year":"2013","unstructured":"Zaidan M, Lescure FX, Broch\u00e9riou I, et al. Tubulointerstitial nephropathies in HIV-infected patients over the past 15 years: a clinico-pathological study. Clin J Am Soc Nephrol. 2013;8(6):930\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1940_CR39","first-page":"295","volume":"58","author":"AB Hill","year":"1965","unstructured":"Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58(5):295\u2013300.","journal-title":"Proc R Soc Med"},{"key":"1940_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-025-01867-6","author":"X Wen","year":"2025","unstructured":"Wen X, Cai L, Gao A, et al. Pharmacovigilance analysis of drug-induced hypofibrinogenemia using the FDA Adverse Event Reporting System. Int J Clin Pharm. 2025. https:\/\/doi.org\/10.1007\/s11096-025-01867-6.","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"1940_CR41","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc JL, Sommet A, Bagheri H, et al. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1940_CR42","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s11096-023-01697-4","volume":"46","author":"CL Oliveira","year":"2024","unstructured":"Oliveira CL, Duarte-Ramos F, Alves da Costa F, et al. Effects of inpatient creatinine testing frequency on acute kidney injury identification and staging: a historical cohort study. Int J Clin Pharm. 2024;46(3):623\u201330.","journal-title":"Int J Clin Pharm"},{"issue":"4","key":"1940_CR43","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1053\/j.ajkd.2015.02.337","volume":"66","author":"ME Grams","year":"2015","unstructured":"Grams ME, Sang Y, Ballew SH, et al. A meta-analysis of the association of estimated GFR, albuminuria, age, race, and sex with acute kidney injury. Am J Kidney Dis. 2015;66(4):591\u2013601.","journal-title":"Am J Kidney Dis"},{"key":"1940_CR44","doi-asserted-by":"publisher","first-page":"5605634","DOI":"10.1155\/2017\/5605634","volume":"2017","author":"S Nie","year":"2017","unstructured":"Nie S, Tang L, Zhang W, et al. Are there modifiable risk factors to improve AKI? Biomed Res Int. 2017;2017:5605634.","journal-title":"Biomed Res Int"},{"issue":"8","key":"1940_CR45","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00134-015-3934-7","volume":"41","author":"EA Hoste","year":"2015","unstructured":"Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41(8):1411\u201323.","journal-title":"Intensive Care Med"},{"issue":"10","key":"1940_CR46","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40266-017-0484-4","volume":"34","author":"S Khan","year":"2017","unstructured":"Khan S, Loi V, Rosner MH. Drug-induced kidney injury in the elderly. Drugs Aging. 2017;34(10):729\u201341.","journal-title":"Drugs Aging"},{"issue":"11","key":"1940_CR47","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/ki.2010.318","volume":"78","author":"LC Herlitz","year":"2010","unstructured":"Herlitz LC, Mohan S, Stokes MB, et al. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int. 2010;78(11):1171\u20137.","journal-title":"Kidney Int"},{"issue":"10","key":"1940_CR48","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1681\/ASN.2012080857","volume":"24","author":"J Tourret","year":"2013","unstructured":"Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol. 2013;24(10):1519\u201327.","journal-title":"J Am Soc Nephrol"},{"key":"1940_CR49","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","volume":"125","author":"AS Ray","year":"2016","unstructured":"Ray AS, Fordyce MW, Hitchcock MJ. Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Antiviral Res. 2016;125:63\u201370.","journal-title":"Antiviral Res"},{"issue":"1","key":"1940_CR50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2352-4642(18)30335-3","volume":"3","author":"ST Bird","year":"2019","unstructured":"Bird ST, Swain RS, Tian F, et al. Effects of deferasirox dose and decreasing serum ferritin concentrations on kidney function in paediatric patients: an analysis of clinical laboratory data from pooled clinical studies. Lancet Child Adolesc Health. 2019;3(1):15\u201322.","journal-title":"Lancet Child Adolesc Health"},{"issue":"4","key":"1940_CR51","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1111\/j.1523-1755.2004.00927.x","volume":"66","author":"RL Mehta","year":"2004","unstructured":"Mehta RL, Pascual MT, Soroko S, et al. Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int. 2004;66(4):1613\u201321.","journal-title":"Kidney Int"},{"issue":"2","key":"1940_CR52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000510455","volume":"7","author":"C Liu","year":"2021","unstructured":"Liu C, Yan S, Wang Y, et al. Drug-induced hospital-acquired acute kidney injury in China: a multicenter cross-sectional survey. Kidney Dis (Basel). 2021;7(2):143\u201355.","journal-title":"Kidney Dis (Basel)"},{"issue":"2","key":"1940_CR53","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s11096-020-00972-y","volume":"42","author":"SB Qin","year":"2020","unstructured":"Qin SB, Zhang XY, Fu Y, et al. The impact of the clinical pharmacist-led interventions in China: a systematic review and Meta-Analysis. Int J Clin Pharm. 2020;42(2):366\u201377.","journal-title":"Int J Clin Pharm"},{"issue":"3","key":"1940_CR54","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s11096-019-00816-4","volume":"41","author":"F Al Raiisi","year":"2019","unstructured":"Al Raiisi F, Stewart D, Fernandez-Llimos F, et al. Clinical pharmacy practice in the care of Chronic Kidney Disease patients: a systematic review. Int J Clin Pharm. 2019;41(3):630\u201366.","journal-title":"Int J Clin Pharm"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01940-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-01940-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01940-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:05:36Z","timestamp":1763557536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-01940-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1940"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-01940-0","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"7 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FAC is an associate editor for IJCP but was not involved in handling the manuscript. The remaining authors have no conflicts of interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}